11 results about "Mebendazole" patented technology

This invention relates to the field of chemical pharmaceuticals, and more particularly to a mebendazole crystal form and its preparation method. The mebendazole crystal form has a single-crystal structure belonging to the triclinic crystal system; space group Triclinic P; cell parameters a = 6.10 Å, b = 15.69 Å, c = 20.35 Å; α = 94.14°; β = 97.22°, γ = 90.70°, V = 1926 Å. 3 The optimization and development of the crystalline form of p-toluimidazole provided by this invention is of great value.

This document provides methods and materials for treating hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g., kidney stone disease). For example, methods and materials for using one or more compounds that can activate oxalate transport to treat a mammal (e.g., a human) having hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g., kidney stone disease) are provided. In some cases, one or more of atorvastatin, cinacalcet, cyproheptadine, vortioxetine, pizotifen, ritonavir, dronedarone, thioridazine, nilotinib, bexarotene, mebendazole, racecadotril, pefloxacin, cabazitaxel, oxibendazole, pyridostigmine, olanzapine, trifluoperazine, AZ-5104, centrimonium, cladribine, ponatinib, dasatinib, and erlotinib can be administered to a mammal (e.g., a human) having hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g., kidney stone disease) to treat the mammal.

The application discloses a kind of R8 and Tf co-modified mebendazole liposome targeted preparation and its preparation method, application, belong to the field of biological medicine. In view of the poor solubility of mebendazole in water, difficult to penetrate blood-brain barrier, the problem of insufficient tumor targeting in brain glioma treatment, the application adopts film hydration-step modification process, and octaarginine (R8) and targeting ligand transferrin (Tf) are simultaneously modified on the surface of mebendazole-loaded liposome, and the preparation prepared by the application has an encapsulation efficiency of not less than 95%. The preparation can break through blood-brain barrier and precisely enrich in brain glioma lesions, and the in-vivo tumor inhibition rate is more than 90%, with low toxicity and side effects. The preparation can be used for preparing brain glioma therapeutic drugs, and provides a new drug for targeted treatment of brain glioma.

The invention provides a mebendazole HP-beta-cyclodextrin clathrate compound. The mebendazole HP-beta-cyclodextrin clathrate compound is prepared from mebendazole and HP-beta-cyclodextrin, wherein the mebendazole HP-beta-cyclodextrin clathrate compound is prepared from the mebendazole and the HP-beta-cyclodextrin; wherein the mebendazole is positioned in a cavity of the HP-beta-cyclodextrin. According to the mebendazole HP-beta-cyclodextrin inclusion compound provided by the invention, the mebendazole and the HP-beta-cyclodextrin are prepared into the inclusion compound, so that the water solubility of the mebendazole is improved by 18333 times and reaches 6.05 mg / mL, which is the best result obtained so far. In addition, the in-vitro PK research shows that the inclusion compound releases 80% of mebendazole within 5 min, while the pure drug only releases 20% under the same condition; in the in-vivo PK research, the bioavailability is almost doubled, which indicates that the prepared toluene imidazole HP-beta-cyclodextrin inclusion compound can be clinically applied as a potential anti-cancer drug.

【Solution】A composition and method for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on the skin. Preferred benzimidazole compounds include mebendazole. The therapeutic composition preferably contains 0.05 to 0.20% by weight of mebendazole in an aqueous or non-aqueous carrier or vehicle including creams, gels, lotions, liquids, emulsions, microemulsions, aerosol sprays, non-aerosol sprays, serums, solutions, suspensions, or ointments, may contain up to 20.0% of mebendazole, and is applied at least once a day over a treatment period of at least two weeks, resulting in a reduction in the appearance of skin cytotoxic CD+8 T cells, papules, pustules, swelling, redness or inflammation, and / or itching at the affected site compared to pre-treatment levels.

The invention relates to the technical field of biological medicines, and particularly discloses application of mebendazole in preparation of a medicine for treating metabolism-related fatty liver diseases. Mebendazole has a remarkable blood fat reducing effect and can remarkably reduce the level of total cholesterol and / or triglyceride and / or low-density lipoprotein in serum; the weight can be reduced, the fatty liver can be improved, and wide application prospects are achieved for obese people. The medicine is simple and convenient to take and easy to absorb by oral administration. In addition, mebendazole is easy to obtain, and compared with other imported drugs, the mebendazole is low in price, high in cost performance, easy to accept by patients and convenient to transport and store.

The present invention provides mebendazole for use in the treatment or prevention of a chronic inflammatory disease, and in particular wherein the chronic inflammatory disease is an autoimmune disease, such as sarcoidosis, systemic lupus erythematosus (SLE), Huntington's disease, end-stage kidney disease, systemic sclerosis (also known as scleroderma), myositis, type 1 diabetes, multiple sclerosis, sicca syndrome, rheumatoid arthritis, psoriasis, primary biliary cirrhosis, autoimmune hepatitis, Graff's disease, Edison's disease, tuberculosis, Crohn's disease, and the like. , ulcerative colitis, inflammatory bowel disease, Alzheimer's disease, and celiac disease. Also provided is a method for treating or preventing a chronic inflammatory disease comprising administering an effective amount of mebendazole or a pharmaceutical composition of mebendazole. Also provided is the use of mebendazole for the preparation of a medicament for the treatment of chronic inflammatory diseases.

The invention discloses application of MoMtg1 protein and a coding gene thereof in regulation and control of growth, development and pathogenicity of magnaporthe oryzae. The deletion of the MoMTG1 gene can lead to slow growth of magnaporthe oryzae, reduction of sporulation quantity, conidium malformation and great reduction of pathogenicity to susceptible rice. The micromolecular compound mebendazole obtained through virtual screening by taking the MoMTG1 coding protein as a target has a good prevention and treatment effect on rice blast. Therefore, the MoMTG1 coding protein can be used as a medicament target, and has a good application prospect in research and development of novel targeted bactericides and prevention and control of diseases.

The present invention discloses the application of MoMtg1 protein and its encoding gene in regulating the growth and pathogenicity of rice blast fungus. MoMTG1 Gene deletion will lead to slow growth of rice blast fungus, reduced spore production, deformed conidia, and a significant decrease in pathogenicity to susceptible rice. MoMTG1 The small molecule compound mebendazole obtained by virtual screening has a good control effect on rice blast by targeting the encoded protein. MoMTG1 The encoded protein can be used as a drug target and has good application prospects in the development of new targeted fungicides and disease prevention and control.

The invention relates to the technical field of medicinal chemistry, in particular to application of mebendazole in preparation of a medicine with an osteosarcoma prevention and / or treatment effect. The invention provides a brand new application of mebendazole. Researches show that mebendazole can significantly inhibit proliferation, invasion and migration capabilities of osteosarcoma cells in vitro, can inhibit in-situ growth of osteosarcoma cells in vivo, and significantly reduces the number and area of pulmonary metastatic nodules; therefore, mebendazole serving as an active ingredient is used for preparing the medicine with the effect of preventing and / or treating osteosarcoma, especially the medicine with the effect of preventing and / or treating metastasis, and has a wide application prospect.

Embodiments of the present disclosure relate to use of Mebendazole, a tyrosine kinase inhibitor or both in combination to treat a coronavirus infection in a subject.